Findings

What do systematic reviews say?

45 questions · 45 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 17.8%GRADE not reported 5 · 11.1%Very low 2 · 4.4%Low 7 · 15.6%Moderate 20 · 44.4%High 3 · 6.7%

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MD‐ICS/LABA · Adolescent sand adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
1
Studies not reported
GRADE not reported

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
1
Studies not reported
GRADE not reported

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
1
Studies not reported
GRADE not reported

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
1
Studies not reported
GRADE not reported

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
1
Studies not reported
GRADE not reported

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All cause AEs ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3188(3 RCTs)

The intervention showed no clear difference in all cause AEs ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3188(3… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.96 [0.91, 1]
3 studies · 3188 participants
Moderate

Intervention not reported

All cause AEs ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2039(2 RCTs)

The intervention showed no clear difference in all cause AEs ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2039(2… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.92 [0.85, 1]
2 studies · 2039 participants
Moderate

Intervention not reported

All cause SAEs ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3187(3 RCTs)

The intervention showed no clear difference in all cause SAEs ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3187(3… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.13 [0.85, 1.5]
3 studies · 3187 participants
Moderate

Intervention not reported

All cause SAEs ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2039(2 RCTs)

The intervention showed no clear difference in all cause SAEs ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2039(2… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.05 [0.76, 1.47]
2 studies · 2039 participants
Moderate

Intervention not reported

Severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 813(1 RCT)

The intervention showed no clear difference in severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants:… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1 [0.35, 2.83]
1 study · 813 participants
Low

Intervention not reported

Severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 815(1 RCT)

The intervention showed no clear difference in severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants:… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.57 [0.17, 1.93]
1 study · 815 participants
Low

Intervention not reported

Asthma‐related SAEs ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3188(3 RCTs)

The intervention showed no clear difference in asthma‐related SAEs ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants:… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.52 [0.85, 2.69]
3 studies · 3188 participants
Moderate